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ABSTRACT: This issue brief provides benchmarks, based on empirical analyses 
of 2002 data, for evaluating the quality of pharmaceutical care under the Medicare 
Part D prescription drug benefit. The analyses cover all major classes of pharma-
ceuticals used by beneficiaries with one of eight chronic conditions. Common 
patterns observed include: 1) a mounting disease burden is associated with 
increasingly complex medication regimens in every group, and 2) the intensity 
and persistence of drug use tend to rise with disease burden up to a point, before 
declining for beneficiaries with the greatest morbidity. The study concludes that 
neither traditional drug quality indicators nor new quality assurance mechanisms 
mandated by law are well aligned to capture suboptimal medication use at either 
end of the spectrum of disease burden in the Medicare population. A holistic 
approach to medication management is needed to ensure that Part D plans meet 
beneficiaries and policymakers’ expectations for high-quality care. 
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It is well known that Medicare beneficiaries are heavy users of prescription medi-
cations. This fact dominated the policy debate over the voluntary prescription drug
This issue brief is based on Medication Use by Aged and Disabled Medicare Beneficiaries 
Across the Spectrum of Morbidity: A Chartbook, published by the Peter Lamy Center on 
Drug Therapy and Aging at the University of Maryland Baltimore in 2007. To obtain 
a copy, please visit the center’s Web site at www.pharmacy.umaryland.edu/lamy. 
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benefit that became available in January 2006. Much 
less is known about the quality and effectiveness of 
medication use by beneficiaries. This is partly due to the 
federal government’s delay in releasing prescription 
drug data from Part D plans, but the problem will not 
be solved simply by making Part D prescription claims 
available to researchers. A more fundamental problem 
is that there are no systematic, evidence-based guide-
lines available to evaluate medication regimens of older 
patients, particularly those with complex morbidity. 
Building the evidence base for appropriate 
drug therapy for Medicare beneficiaries must begin 
with an empirical, population-level assessment of how 
medication regimens vary across the continuum of 
disease burden. To accomplish this objective, the 
researchers used data from the period prior to the 
implementation of the new drug benefit to describe 
the breadth, intensity, and persistence of medication 
regimens for the Medicare population as a whole and 
for beneficiaries with eight common chronic condi-
tions: diabetes, depression, dementia, chronic obstruc-
tive pulmonary disease (COPD), arthritis, hypertension, 
ischemic heart disease, and heart failure. 
Two features of this study distinguish it from 
previous research on medication use by Medicare 
beneficiaries. First, it examines drug utilization pat-
terns for beneficiaries with each of these chronic con-
ditions in the larger context of their overall disease 
burden. Over their lifetimes, few Medicare beneficiar-
ies suffer from single diseases with well-accepted, 
evidence-based treatment recommendations. Rather, 
most ultimately develop multiple conditions, for which 
treatment guidelines are either lacking or ambiguous in 
the presence of significant comorbidity. Geriatricians 
have developed various clinical recommendations and 
best practice statements for dealing with complex 
morbidity in older patients. The development of evi-
dence-based guidelines for treating complex morbidity 
has proven elusive, however, in part due to scant 
epidemiologic data describing how treatment patterns 
for particular chronic conditions change with rising 
morbidity. This study was designed to help build this 
evidence base. 
A second unique feature of the study is that it 
takes into account the prescription drugs used to treat 
all of the diseases that beneficiaries suffer—not just 
those specific to the eight chronic conditions. This 
analysis examines how beneficiaries’ medication regi-
mens evolve with accumulating morbidity, highlighting 
areas of potential concern regarding underuse, overuse, 
and inappropriate use of medication therapy for par-
ticular segments of the chronically ill population. 
 
METHODOLOGY 
The sample for the study (N=8,455) was selected from 
the 2002 Medicare Current Beneficiary Survey (MCBS). 
The MCBS collects extensive information on prescrip-
tion drug utilization and spending from self-reports and 
reviews of medication containers. The MCBS also 
provides claims data for Part A (inpatient and outpa-
tient hospital and post-acute services) and Part B (phy-
sician and other provider services) for each respondent. 
Diagnostic indicators from the claims data, together 
with self-reports of chronic conditions, were used to 
define the eight disease cohorts. In order to capture the 
full spectrum of rising disease burden, each cohort was 
stratified into 10 equal-size deciles, based on cumula-
tive health care spending during the year from all payer 
sources, including beneficiaries’ out-of-pocket ex-
penses.1 Medication statistics were computed at the in-
dividual beneficiary level, aggregated by disease co-
hort and decile of disease burden, and then weighted to 
be nationally representative of the community-dwelling 
Medicare population. Beneficiaries enrolled through 
the Medicare+Choice program (privately administered 
plans, now called Medicare Advantage) and those in 
long-term care facilities were excluded due to lack of 
critical data elements. 
The study focused on four sets of indicators 
designed to benchmark the quality and effectiveness 
of beneficiaries’ medication use before the advent of 
Part D drug coverage. The first indicator is the fraction 
of total health care spending devoted to prescription 
drugs. This captures changes in the allocation of 
health resources used to treat beneficiaries with rising 
disease burden. 
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The second set of indicators depicts the in-
creasing breadth and complexity of medication utiliza-
tion with rising disease burden. Two recognized meas-
ures of drug regimen complexity were profiled: the 
number of unique therapeutic categories and the num-
ber of unique pharmacologic classes represented in 
each beneficiary’s annual course of drug therapy. The 
study used the United States Pharmacopoeia (USP) 
classifications published in December 2004 as guid-
ance for Part D plans in 2006.2
The third set of indicators shows how average 
intensity of medication use evolves with rising disease 
burden. Two measures were employed here as well. 
One is the average number of fills per medication-
intensive condition diagnosed in Medicare claims. 
Medication-intensive comorbidity was identified using 
the Centers for Medicare and Medicaid Services 
(CMS) Prescription Drug Hierarchical Coexisting 
Conditions (RxHCC) model used to risk-adjust pay-
ments to Medicare Part D plans.3 The other intensity 
measure is the average number of prescription fills per 
pharmacologic class represented in each beneficiary’s 
medication regimen. 
The final set of indicators drilled down to 
the prevalence and persistence of specific drugs 
used to treat particular medical problems. This set 
included four measures. First is the annual prevalence 
of every therapeutic drug category used by at least 
5 percent of the beneficiaries in each disease cohort 
(typically 20 to 25 drug groups). Next is the mean 
number of prescription fills per user of drugs in each 
category (this measure captures the persistence of 
use over the year). Additional measures gauged the 
utilization of drugs recommended by consensus 
guidelines for the treatment of the eight chronic dis-
eases. Here, too, drug use is characterized by any use 
(prevalence) and number of annual prescription fills 
among users (persistence of use). The full report con-
tains an extensive set of appendix tables that character-
izes each study cohort by sociodemographic factors, 
health status measures, and selected health system 
utilization variables. 
 
Figure 1. Relationship of Drug Spending to Total Medical















This issue brief highlights a small sample of the find-
ings presented in the overall study.4
 
The Medicare Population 
Prescription drugs represent a significant component of 
the medical care received by Medicare beneficiaries, 
accounting for 20 percent to 31 percent of total spend-
ing for the average individual across the eight condi-
tions studied. Beneficiaries with diabetes and hyperten-
sion had the highest average shares of spending 
devoted to prescription drugs (31% each), while bene-
ficiaries with heart failure and COPD had the lowest 
shares (20% and 21%, respectively). Figure 1 plots 
drug spending and total medical expenditures for 
community-dwelling beneficiaries as a function of ris-
ing disease burden. On average, Medicare beneficiaries 
spent $1,700 on prescription drugs in 2002. Spending 
rose at a nearly constant rate from $103 in decile 1 to 
decile 7 before flattening out in the top three deciles, 
finally reaching $2,924 in decile 10. Total medical 
spending exhibits a very different growth pattern. The 
average beneficiary consumed $10,210 in all medical 
services in 2002, ranging from $363 in the lowest dec-
ile to $49,519 in the highest. The sharply rising expen-
diture rates from the sixth through the tenth deciles are 
primarily a result of hospitalization. About one of five 
beneficiaries was hospitalized that year and 90 percent 
of this group fell in the top three spending deciles. 
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Figure 2. Prescription Drug Spending as a Percent of Total Medical 
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These differential trends mean that the propor-
tion of medical spending devoted to prescription drugs 
doubled, from 21 percent in the first decile to a peak of 
42 percent in decile 4, and then fell back sharply to just 
7 percent in decile 10 (Figure 2). The declining drug share 
in the top (e.g., higher cost) half of the distribution is 
not surprising, because drugs are cheap compared with 
hospitalization. However, the rising proportion of spend-
ing devoted to prescription drugs in the bottom half of 
the distribution is worth noting. While there is no inher-
ently “right” fraction of health care that should be devoted 
to prescription drugs, to the extent that drugs substitute 
for more expensive services, the middle of the curve 
seen in Figure 1 may reflect the most efficient alloca-
tion of services across the spectrum of morbidity. 
Figure 3. Relationship of Drug Use to Medication-Intensive
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Figure 4. Intensity of Prescription Drug Use per
Medication-Intensive Condition (RxHCC) for
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The next two figures show how prescription 
drug use and the conditions for which they are pre-
scribed vary with increasing disease burden. The upper 
line in Figure 3 plots the number of annual adjusted 
prescription fills. This measure takes into account the 
fact that some prescriptions contain more than a single 
medication (e.g., codeine plus acetaminophen). For 
such combination products, each pharmacological class 
represented in the prescription is counted as a separate 
fill.5 The relationship between the number of adjusted 
prescription fills and spending decile is nearly linear 
from decile 1 (4.3 fills) to decile 9 (55.3 fills), before 
falling back slightly in decile 10 (52.4 fills). The lower 
line presents counts of medication-intensive conditions 
based on the RxHCC metric, and rises slowly from 1.1 
condition per beneficiary in decile 1 to 10.5 conditions 
per beneficiary in decile 10. 
 
 
Differential rates of increase in these two indi-
cators—number of adjusted fills and counts of medica-
tion-intensive conditions—generate the “inverted U” 
pattern observed in Figure 4. The ratios range from 1.9 
fills per condition in decile 1 to a peak of 9.7 in decile 
5 and then back to 5.5 fills per condition in decile 10. 
A similar pattern was observed for each of the eight 
disease cohorts, with intensity peaking in the middle of 
the range, between 25 percent and 58 percent above 
levels observed at either extreme. This is a basic find-
ing of this study: while higher levels of intensity of 
drug therapy do not necessarily imply better treatment, 
the fact that intensity levels are systematically lower 
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for beneficiaries with both low and high disease burdens 
may signal that chronic medications are being underuti-
lized and/or misutilized by these individuals. Further, the 
broadly similar patterns in Figures 2 and 4 suggest that 
intensity of drug use is an important factor underlying the 
rising and then falling drug share of spending observed. 
Figure 5 shows another way of measuring inten-
sity of drug use among community-dwelling benefici-
aries. The denominator of this measure—adjusted 
prescription fills—is the same as in the previous figure. 
The numerator is the number of USP pharmacologic 
classes represented in each beneficiary’s drug regimen. 
Pharmacologic classes represent the unique properties 
of the drug that make them medically effective. The 
ratio of adjusted fills to pharmacologic classes produces 
an “inverted U” pattern, as seen in Figures 2 and 4. 
However, the curve in Figure 5 is flatter at the top, indi-
cating a broad plateau in the mean number of prescrip-
tions filled per drug class before the rate begins to decline 
after the seventh decile of medical spending. The inter-
pretation of this pattern is similar to that for Figure 4. 
High intensity of drug use is not desirable per se, except 
to the extent that it is driven by medications for chronic 
conditions that generally should be administered 
throughout the year in order to be optimally effective. 
 
 
Figure 5. Intensity of Prescription Drug Use per Pharmacologic 
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* Adjusted to account for combination products containing drugs in two or more pharmacologic classes.
 
Medicare Beneficiaries with Diabetes 
This section summarizes findings relating to treatment 
of diabetes in the Medicare population. The sample for 
this analysis comprised 1,956 community-dwelling 
beneficiaries with the disease in 2002. The focus is on 
six drugs and drug classes widely recommended by 
diabetes treatment guidelines as a means to help prevent 
or delay complications of the disease. The guidelines 
recommend regular use of antidiabetic drugs (primarily 
oral hypoglycemics but also insulin in severe cases), 
ACE-inhibitors (or ARBs for people who are intolerant 
of ACE-inhibitors), and statins or other lipid lowering 
agents for those with LDL cholesterol >100 mg/dL. 
Adults with diabetes are also recommended to have an 
annual influenza vaccination and a pneumococcal vac-
cination every five years. In reviewing these findings, 
it is important to recognize that not every older adult 
with diabetes is a candidate for each medication. 
Table 1 shows prevalence rates by spending 
decile for the six recommended agents. Except for 
pneumococcal vaccinations, prevalence rates are low-
est at the bottom of the scale; that is, Medicare benefi-
ciaries who have the least severe disease burden are also 
the least likely to get recommended preventive meas-
ures. That does not imply, however, that those with 
high disease burden are necessarily more likely to re-
ceive these treatments. In fact, the prevalence of oral 
hypoglycemic use is the same in deciles 1 and 10 
(47%), much below the peak of 65 percent in deciles 6 
and 7. Annual flu vaccinations, use of ACE-inhibitors or 
ARBs, and use of statins or other lipid lowering drugs 
also reach peak prevalence rates below decile 10. Only 
insulin use is highest in decile 10, and that reflects se-
verity of diabetes rather than the health risks associated 
with other comorbidities. 
Table 2 shows mean annual prescription fills 
by Medicare beneficiaries with diabetes who used oral 
hypoglycemic agents, ACE-inhibitors or ARBs, dyslip-
idemics, and insulin in 2002. Two features of these 
findings are worth noting. First, given that a typical pre-
scription fill is for a 30-day supply, oral hypoglycemic 
agents are the only preventive treatment in which aver-
age utilization rates approach continuous therapy across 
the year.6 Persistence in use is much lower for the other 
medications. The second point is that persistence rates 
for all four medication classes are lower at the extremes 
of the range of disease burden compared with the middle,
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and the differentials are large. For example, in percentage 
terms, users of oral hypoglycemic agents in decile 10 
had 33 percent fewer annual fills compared with users 
in the peak decile (6). They had 23 percent fewer 
RAASI fills from peak levels, 26 percent fewer fills for 
dyslipidemic agents, and 33 percent fewer insulin fills. 
Equally large differentials are observed between the 
middle and low ends of the disease spectrum. 
With the exception of insulin, these are medi-
cations recommended for most if not all diabetes 
patients. Therefore, the treatment patterns observed 
in Tables 1 and 2 suggest that Medicare beneficiaries 
with this disease are much less likely to receive opti-
mal medication therapy if they happen to be at either 
extreme of the disease burden spectrum. 
 
Medicare Beneficiaries with 
Ischemic Heart Disease 
This section focuses on beneficiaries with ischemic heart 
disease, also known as coronary artery disease (N=2,184). 
Treatment goals for this condition are to reduce the 
probability of cardiac events by modifying the course 
of the disease and to relieve symptoms associated with 
angina. Recommended medications include beta-
blockers, antiplatelet agents, ACE-inhibitors or ARBs, 
and statins or other lipid lowering agents. Nitrates and 
beta-blockers are recommended to control angina pain. 
Overall, 85 percent of the cohort with ischemic 
heart disease filled prescriptions for one or more of the 
drug classes shown in Table 3. However, only in the 
case of cholesterol lowering agents and ACE-inhibitors/ 
ARBs does the annual prevalence exceed half of the 
cohort (52% in each case). On average, 49 percent 
used beta-blockers, 14 percent used antiplatelet agents, 
and 27 percent used nitrates. The prevalence of beta-
blockers, lipid lowering agents, ACE-inhibitors/ARBs, 
and nitrates rises with disease burden, reaching peak 
levels between deciles 4 and 9. Prevalence of antiplate-
let agents is highest in decile 10 (at nearly 30%). 
Table 4 shows the average number of annual 
prescription fills among users of these drugs. The utili-
zation rates exhibit the same pattern seen in Table 2, 
with the mean number of fills rising with disease 
burden to a peak and then gradually falling thereafter. 
Utilization rates for antiplatelet agents peak in decile 4 
(6.7 fills) and then decline by half to 3.5 fills per year 
in decile 9. Peak fill rates for lipid lowering agents and 
nitrates occur in decile 5 (at 7.5 and 6.8 fills, respec-
tively), and ACE-inhibitor/ARB use peaks in decile 6 
(6.8 fills). In each case utilization rates declining by 
between 20 percent and 30 percent by decile 10. Beta-
blocker utilization rates rise from 5.7 fills to a peak of 
6.8 fills per year over a wide swath of the spending dis-
tribution (deciles 2 to 7) before falling back to 4.9 fills 
per annum in decile 10. As in the case of diabetes, 
these utilization patterns suggest that Medicare benefi-
ciaries with ischemic heart disease are much less likely 
to receive optimal medication therapy if they happen to 
be at either extreme of the disease burden spectrum. 
 
Medicare Beneficiaries with 
Other Chronic Diseases 
The full report contains additional charts characterizing 
drug use for beneficiaries with other chronic diseases 
including arthritis, COPD, depression, dementia, heart 
failure, and hypertension. Similar patterns are found to 
those exhibited here; namely, drug regimen complexity 
increases with overall disease burden, but the intensity 
and persistence of use generally exhibit the “inverted U” 
patterns seen in Figures 2, 4, and 5. 
 
DISCUSSION 
These recurrent utilization patterns have important 
implications for the quality and effectiveness of medi-
cation use by Medicare beneficiaries. For beneficiaries 
with the lowest disease burden, rising morbidity is ini-
tially accompanied by increases in every benchmark 
measure—drug spending relative to other health ser-
vices, breadth of drug regimen, intensity of use per 
medication-intensive condition and per drug class, 
and persistence of use for specific agents. One plausi-
ble explanation for these patterns is a version the “sur-
veillance hypothesis,” which posits that persons with 
multiple diseases have more frequent physician con-
tacts, thereby increasing the likelihood of receiving 
necessary and appropriate care.7 This interpretation is
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bolstered by the fact that, in every disease studied, 
prevalence and persistence rates for recommended 
therapies initially increase with additional health care 
spending. This might be considered a good thing 
except that it implies that beneficiaries who do not 
have these additional health system contacts may 
be systematically undertreated. Indeed, it is possible 
that failure to receive recommended therapies when 
disease burden is low is a root cause of the burden 
ultimately rising. 
A reversal of these patterns is observed at the 
other end of the disease spectrum, where increasing 
morbidity is associated with declining intensity and 
persistence in medication use. It would seem that phy-
sician surveillance (if indeed that is the cause of im-
proved compliance with recommended therapies) has 
its limits. Similar patterns have been reported in prior 
studies, leading to the notion that competing demands 
for physician time may seriously compromise quality 
of care among patients with multiple morbidity.8 This 
conclusion is based on the assumption that failure to 
receive recommended therapies at recommended doses 
is a sign of poor quality. By that criterion, the medica-
tion patterns observed at the upper end of the disease 
spectrum would receive very low grades. Not only do 
many of the sickest beneficiaries fail to receive medi-
cations called for in disease treatment guidelines, the 
persistence of use among those who do is generally far 
below optimal levels. 
A contrasting viewpoint, held by many geriat-
ricians, is expressed well by Durso: “Attempting to 
manage all relevant illnesses or syndromes with equal 
vigor according to relevant clinical care guidelines may 
be impractical, harmful, and negatively impact the pa-
tient’s quality of life. For some particularly frail indi-
viduals, fastidious management of multiple conditions 
may be unduly burdensome, costly, or lead to un-
wanted disease-drug or drug-drug interactions”9 Yet, 
the medication patterns observed in this study also fail 
the geriatrician’s credo, since too many chronic medi-
cations are being taken at such apparently suboptimal 
levels to do much good (and may well be doing harm). 
A better strategy would be to winnow out less-effective 
medications entirely and stress better adherence with those 
that are truly critical to patient health and well-being. 
Arguably the most appropriate utilization pat-
terns observed in the study occur in the middle of the 
spectrum of disease burden. Medication intensity meas-
ured both at the pharmacological class level and by RxHCC 
reach peak levels for beneficiaries with moderate dis-
ease burden. Persistence of medication use for agents 
recommended by disease guidelines also peaks in the 
middle of the spectrum for beneficiaries with diabetes, 
COPD, ischemic heart disease, heart failure, and hyper-
tension. Moreover, the peak persistence levels observed 
for these medications are generally high enough to achieve 
therapeutic effectiveness over the course of a year. 
Discovering the factors associated with desirable pat-
terns of use should thus be a priority for future research. 
It is important to stress that these findings reflect 
information provided by Medicare beneficiaries. Any 
direct inferences to physician prescribing patterns are 
unwarranted. Although access to prescription drugs 
requires the active participation of physicians, that does 
not guarantee the prescriptions will be filled or refilled 
according to directions. It is estimated that 20 percent or 
more of all prescriptions are never filled and an even 
higher percentage are not refilled in a timely fashion.10 
The most common reasons patients give for failing to 
fill prescriptions are cost, fear of adverse reactions, lack 
of perceived need, forgetfulness, and difficulty getting 
to pharmacies. These reasons may contribute to the 
suboptimal utilization patterns observed in this study. 
This is clearly another priority area for future research. 
It is also important to note that the survey and 
claims data used in this empirical analysis are subject to 
error. A technical appendix to the report considers vari-
ous sources of error and potential biases in the presen-
tations, including underreporting of drug events, a 
“disappearing denominator” problem when deaths and 
hospitalizations cluster in the top spending deciles, and 
the possibility that the ubiquitous “inverted U” pattern 
is an artifact of a changing mix in days supply or drug 
switching regimens over the spectrum of morbidity. 
None of these factors was shown to materially affect 
the conclusions of the study.
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POLICY IMPLICATIONS 
The study findings are based on observational data and 
do not control for factors other than disease burden. 
Nonetheless, the recurrent pattern of apparent subopti-
mal medication utilization among Medicare beneficiar-
ies at both ends of the disease spectrum is strong 
enough to demand the attention of policymakers. Of 
particular concern is the fact that available clinical 
tools designed to improve the quality of medication 
therapy are not well aligned to address these problems. 
Current drug utilization evaluation protocols, 
including drug use review and consensus guidelines for 
pharmaceutical care of specific diseases, typically pro-
vide little or no guidance on whether recommended 
therapies should vary depending on the patient’s over-
all disease burden.11 Standard drug use review programs 
employed by pharmacy benefit managers and pharmacy 
providers focus on potentially preventable adverse 
events from individual drugs or specific drug combina-
tions, rather than possible adverse health consequences 
of polypharmacy or inadequate compliance with therapy 
guidelines. Medication quality assurance programs includ-
ing ACOVE, SCRIPT, and the new Pharmacy Quality 
Alliance (PQA) are beginning to address noncompliance 
with guidelines.12 For example, PQA’s preliminary guide-
lines use time between refills to flag suboptimal drug 
adherence for statins and other selected cardiovascular 
medications. Neither the PQA nor earlier efforts, how-
ever, address the larger issue of how best to treat a sin-
gle disease in the context of the whole patient. This is a 
two-sided problem. For patients with high disease bur-
den, aggressive attempts to follow disease-specific 
guidelines for each and every condition are unlikely to 
succeed and, even if they do, the higher drug load from 
polypharmacy may produce poorer overall outcomes. 
The problem of noncompliance is very different at the 
other end of the spectrum. Patients with low disease 
burden who fail to receive recommended therapies or 
who are nonadherent users are difficult to reach with 
current drug use evaluation tools for the simple reason 
that they have few contacts with the medical system. 
The Medication Therapy Management (MTM) 
programs mandated for Part D prescription drug plans 
represents a revolutionary departure from the traditional 
disease–drug approach to medication quality improve-
ment. MTM programs are required to evaluate the en-
tire drug regimen of Medicare beneficiaries who meet 
annual thresholds for drug spending, polypharmacy, 
and multiple morbidity. The focus on the whole patient 
is a positive step, as is the federal rule that permits (but 
does not require) pharmacists to conduct the reviews. 
On the other hand, there are several negative 
aspects of the MTM program that will limit its effective-
ness in addressing the medication problems identified 
in this study. First, except possibly in managed care 
plans, MTM providers do not have access to medical 
claims or prescriber records, which means that review-
ers must infer disease from drug use. This is problem-
atic in that some drug classes are used to treat various 
conditions (e.g., antihypertensives, anti-inflammatory 
agents, and autonomic agents), as well as the obvious 
fact that untreated conditions will be missed. The sec-
ond problem is that stand-alone prescription drug plans 
have a financial incentive to minimize drug costs rather 
than optimize drug therapy from the standpoint of ei-
ther patient well-being or total health care costs. Third, 
there are no specific federal regulations regarding how 
MTM reviews are conducted which, when combined 
with the aforementioned financial incentives, may lead 
drug plans to skimp on the reviews. Fourth, the criteria 
for patient eligibility for MTM services are based on 
drug costs, not total health care costs. Although drug 
costs may be an appropriate flag for certain types of 
problems, total costs are a better way to capture the 
spectrum of problematic medication use. Indeed, it is 
possible that high drug spenders are among the most 
compliant drug users. Finally, because of the focus on 
high drug spending, MTM reviews fail to identify 
problems of noncompliance with proven preventive 
therapies among low spenders. Addressing this prob-
lem may produce greater long-term returns than policy 
tools focused exclusively on high-cost cases. 
In addition to the MTM program, the Medicare 
Modernization Act introduced several initiatives focused 
on improving treatment for beneficiaries with multiple 
high-cost chronic diseases in the fee-for-service and 
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managed care sectors. Medicare Health Support (formerly 
the Chronic Care Improvement Program) is a demon-
stration program designed to test whether capitated care 
management services can pay for themselves in reduced 
Medicare costs for fee-for-service beneficiaries with 
diabetes and heart failure. The MMA also authorized 
Special Needs Plans (SNPs), which are Medicare Advan-
tage plans with enrollments that focus on dual eligibles 
(those eligible for both Medicare and Medicaid), insti-
tutionalized beneficiaries, or beneficiaries with selected 
chronic conditions. Both Medicare Health Support organi-
zations and SNPs have financial incentives to reduce 
traditional Medicare service costs, and one of the ways 
that can be accomplished is through good medication 
management. But it is also possible to reduce costs 
through myriad other mechanisms that might actually 
compromise quality of medication use. 
The most recent CMS quality improvement 
effort is the Physician Quality Reporting Initiative 
(PQRI), authorized by the Tax Relief and Health Care 
Act of 2006.13 Under PQRI, eligible practitioners are 
able to earn payment bonuses for successfully report-
ing compliance with specified quality measures. As of 
this writing, there are 134 quality indicators, of which 
45 deal with medication therapy.14 These draw heavily 
on existing evidence-based guidelines, none of which 
consider the overall disease burden of the patient. The 
PQRI program has the potential to significantly change 
practice patterns because of its direct link to reim-
bursement. Whether the bonuses are sufficiently high 
to realize this potential is yet to be determined. More-
over, the PQRI program is no panacea for some of the 
most significant problems associated with medication 
management of Medicare beneficiaries. As it stands, 
physicians will receive extra payment if they follow 
PQRI prescribing standards, whether patients fill the 
prescriptions or not. The payments will have little ef-
fect on suboptimal prescribing for beneficiaries who 
seldom connect with the medical system. And there is 
the possibility of real harm if the quality measures are 
blindly followed without taking into account the 
wishes of patients or the competing demands imposed 
by significant comorbidity. 
In conclusion, while current drug quality assur-
ance programs and demonstration initiatives may im-
prove prescribing and medication adherence for some 
Medicare beneficiaries, the selective targeting of these 
mechanisms means that the majority of beneficiaries 
with suboptimal medication utilization will either be 
missed altogether or will receive interventions that tar-
get only part of the problem, and not necessarily the most 
important part. It is hoped that the study findings will 
convince policymakers to take a more holistic approach 
to medication management in the Medicare program. 
 
 
Table 1. Prevalence of Drugs Used to Treat and Help Prevent or Delay Complications of Diabetes 
for Medicare Beneficiaries with Diabetes, by Decile of Annual Medical Spending in 2002a 
Prevalence of Medication Use by Spending Decile (%) 
Drug or Drug Class All 1 2 3 4 5 6 7 8 9 10 
Oral hypoglycemic agents 58.2 47.1 55.2 63.3 63.1 57.7 64.8 64.8 57.4 60.1 47.4 
Insulin 6.8 1.3* 2.3* 4.7* 4.1* 5.6* 5.8 5.1 11.1 13.8 14.3 
Renin-angiotensin-aldosterone 
system inhibitors 58.9 38.2 49.0 59.2 61.6 63.4 57.6 66.0 62.8 71.0 59.2 
Dyslipidemics 44.6 22.3 35.1 42.3 51.1 47.5 47.0 45.5 54.2 52.4 47.0 
Flu shot (past year) 70.0 53.9 74.5 65.4 68.2 75.5 73.3 71.0 72.3 78.7 65.9 
Pneumococcal vaccination 
(past 5 years) 29.5 48.5 27.0 32.1 27.2 31.4 30.9 27.7 20.6 21.7 28.8 
a All values weighted to be nationally representative of the population sample frame (beneficiaries having both 
Medicare Part A and B coverage, community-dwelling, in the fee-for-service sector, and completing all survey rounds). 
Note: Values marked with an asterisk have relative standard errors greater than 0.3 and should not be considered statistically stable. 
Source: Medicare Current Beneficiary Survey, 2002. 
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Table 2. Number of Prescription Fills for Drugs Used to Treat and Help Prevent or Delay Complications 
of Diabetes for Medicare Beneficiaries with Diabetes, by Decile of Annual Medical Spending in 2002a 
Mean Annual Prescription Fills for Medication Users by Spending Decileb 
Drug or Drug Class All 1 2 3 4 5 6 7 8 9 10 
Oral hypoglycemic agents 9.1 6.7 7.9 10.3 9.6 9.5 10.3 10.0 8.9 9.4 6.9 
Insulin 5.7 5.7 3.1 5.7 4.8* 4.5 7.6 9.2 4.9 5.0* 6.2 
Renin-angiotensin-aldosterone 
system inhibitors 5.8 5.1 5.0 6.4 5.4 7.0 6.5 5.7 5.3 5.5 5.4 
Dyslipidemics 6.1 4.3 5.0 6.2 5.5 6.8 6.9 6.5 6.7 6.1 5.1 
a All values weighted to be nationally representative of the population sample frame (beneficiaries having both 
Medicare Part A and B coverage, community-dwelling, in the fee-for-service sector, and completing all survey rounds). 
b Restricted to users of each medication. 
Note: Values marked with an asterisk have relative standard errors greater than 0.3 and should not be considered statistically stable. 





Table 3. Prevalence of Drugs Used to Treat Ischemic Heart Disease 
for Medicare Beneficiaries with Ischemic Heart Disease, by Decile of Annual Medical Spending in 2002a 
Prevalence of Medication Use by Spending Decile (%) 
Drug or Drug Class All 1 2 3 4 5 6 7 8 9 10 
Beta blockers 48.8 39.9 45.8 43.9 46.4 49.1 49.3 55.8 54.0 52.3 51.7 
Antiplatelet agents 14.2 2.5* 8.6 2.6* 8.9 11.3 13.7 17.2 25.6 22.2 29.6 
Cholesterol lowering agents 52.0 37.9 57.2 53.3 58.6 56.9 51.0 53.9 56.3 45.1 49.0 
Statins 49.0 34.9 54.6 52.2 53.9 53.1 48.2 50.2 52.1 42.3 48.0 
Other lipid lowering agents 6.9 4.2* 6.1 7.0 7.2 9.3 6.7 9.5 9.9 4.2* 4.8 
ACE-inhibitors 39.1 25.1 34.6 42.1 33.5 41.0 39.2 45.3 47.4 41.0 40.9 
ARBs 15.7 9.4 12.4 14.8 15.4 15.9 17.1 16.2 18.9 19.1 18.1 
Nitrates 27.4 20.2 27.4 20.7 22.0 32.3 30.2 33.8 31.6 24.2 31.5 
Any drug used to treat 
ischemic heart disease 84.9 74.1 85.5 83.7 84.4 88.6 89.0 87.9 87.5 82.4 85.9 
a All values weighted to be nationally representative of the population sample frame (beneficiaries having both 
Medicare Part A and B coverage, community-dwelling, in the fee-for-service sector, and completing all survey rounds). 
Note: Values marked with an asterisk have relative standard errors greater than 0.3 and should not be considered statistically stable. 
Source: Medicare Current Beneficiary Survey, 2002. 
 
Table 4. Number of Prescription Fills for Drugs Used to Treat Ischemic Heart Disease 
for Medicare Beneficiaries with Ischemic Heart Disease, by Decile of Annual Medical Spending in 2002a 
Prevalence of Medication Use by Spending Decile (%) 
Drug or Drug Class All 1 2 3 4 5 6 7 8 9 10 
Beta blockers 6.1 5.7 6.2 6.5 6.6 6.7 6.8 6.6 5.8 5.5 4.9 
Antiplatelet agents 4.7 5.8* 6.3 4.9 6.7 5.7 4.7 5.0 4.0 3.5 4.3 
Cholesterol lowering agents 6.1 5.0 5.7 6.3 5.9 7.5 6.0 6.8 6.2 5.0 5.5 
Statins 5.7 4.6 5.2 5.8 5.8 7.1 5.9 6.3 5.7 4.8 5.3 
Other lipid lowering agents 5.0 6.9 6.2 4.6 4.8 5.3 3.3 5.5 5.1 4.7 3.6 
ACE-inhibitors 6.0 6.0 6.2 6.3 6.6 7.2 6.7 5.8 5.7 5.1 4.7 
ARBs 5.5 5.3 3.9 6.4 6.5 5.9 5.5 6.5 4.9 5.2 5.1 
Nitrates 5.9 5.9 6.1 5.7 5.8 6.8 6.4 6.0 6.2 5.1 5.1 
Any drug used to treat 
ischemic heart disease 21.2 15.5 19.7 21.6 21.6 25.4 21.6 24.3 23.2 18.8 19.3 
a All values weighted to be nationally representative of the population sample frame (beneficiaries having both 
Medicare Part A and B coverage, community-dwelling, in the fee-for-service sector, and completing all survey rounds). 
Note: Values marked with an asterisk have relative standard errors greater than 0.3 and should not be considered statistically stable. 
Source: Medicare Current Beneficiary Survey, 2002. 
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